GlassScriptPhysician profile
Elena Marta Sheets
NPI 1497260038
$5,232.51
in general payments reported to CMS, 2019-2025
26 companies · $790 in 2025
The $790 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,105 · 2022: $998 · 2023: $1,423 · 2024: $918 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,098.22 | 2021-2025 | |
| Abbott Laboratories | $727.72 | 2021-2025 | Jeti Peripheral Catheter, Jeti, Perclose Prostyle |
| Takeda Pharmaceuticals U.S.A., INC. | $403.63 | 2021-2025 | Entyvio, Gattex |
| Boston Scientific Corporation | $250.23 | 2021-2023 | Cre Pro |
| Janssen Scientific Affairs, LLC | $194.38 | 2024-2025 | Tremfya, Remicade, Stelara |
| Celgene Corporation | $187.25 | 2022-2023 | Zeposia |
| Daiichi Sankyo INC. | $165.94 | 2021-2024 | Injectafer |
| Pfizer INC. | $151.07 | 2022-2025 | |
| Qol Medical, LLC | $124.10 | 2021-2025 | Sucraid, Sucraid |
| Novocure INC. | $114.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.06 | 2021-2023 | Trulance |
| Janssen Biotech, INC. | $86.97 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $86.89 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $85.36 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $81.96 | 2021-2024 | Dificid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $77.94 | 2023 | |
| Phathom Pharmaceuticals, INC. | $75.75 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $46.22 | 2021-2023 | Rebyota |
| Ardelyx, INC. | $37.15 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $33.06 | 2024-2025 | Omvoh |
| Evoke Pharma, INC. | $32.45 | 2021 | |
| Redhill Biopharma INC. | $19.93 | 2022 | |
| Aimmune Therapeutics, INC. | $17.79 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $15.77 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.73 | 2022 | |
| Ethicon US, LLC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.